Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.00
-0.79 (-4.20%)
May 14, 2026, 11:05 AM EDT - Market open
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Summit Therapeutics stock have a consensus rating of "Buy" and an average price target of $30.54, which forecasts a 69.67% increase in the stock price over the next year. The lowest target is $12 and the highest is $45.
Price Target: $30.54 (+69.67%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 7 | 8 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 4 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 15 | 16 | 17 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $23 | Strong Buy | Maintains | $30 → $23 | +27.78% | May 4, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $17 → $16 | Hold | Maintains | $17 → $16 | -11.11% | May 1, 2026 |
| Stifel | Stifel | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +150.00% | Apr 8, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $42 → $15 | Strong Buy → Hold | Downgrades | $42 → $15 | -16.67% | Mar 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +66.67% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
8.32M
Revenue Next Year
104.57M
from 8.32M
Increased by 1,157.15%
EPS This Year
-1.07
from -1.44
EPS Next Year
-1.09
from -1.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 61.0M | 377.9M | ||||||
| Avg | 8.3M | 104.6M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 4,442.8% | ||||||
| Avg | - | 1,157.2% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.60 | -0.61 | ||||||
| Avg | -1.07 | -1.09 | ||||||
| Low | -1.58 | -1.63 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.